کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
3943857 1254138 2006 4 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی زنان، زایمان و بهداشت زنان
پیش نمایش صفحه اول مقاله
The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma
چکیده انگلیسی

ObjectiveTo evaluate our experience with the use of bevacizumab in patients with heavily pretreated recurrent ovarian carcinoma who have symptomatic ascites.MethodsFour patients were identified who were previously heavily pretreated for recurrent ovarian carcinoma. Each had symptomatic ascites and required frequent therapeutic paracenteses. Each was treated with bevacizumab with the intent to palliate symptomatic ascites. Clinical data including demographic data and clinicopathologic variables was abstracted.ResultsThe four patients demonstrated symptomatic relief of ascites. Toxicity was manageable in all patients with no grade 3/4 toxicity observed. In addition to symptomatic relief of ascites, no therapeutic paracenteses were required after initiation of therapy with bevacizumab.ConclusionsBevacizumab may be a viable palliative option in patients with end stage ovarian carcinoma who have symptomatic ascites.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Gynecologic Oncology - Volume 102, Issue 3, September 2006, Pages 425–428
نویسندگان
, , , ,